122 related articles for article (PubMed ID: 38497543)
1. Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma.
Li L; Yang W; Pan Y; Ye R; Wang Y; Li S; Jiang H; Zhang Q; Wang X; Yan J
Leuk Lymphoma; 2024 Mar; ():1-16. PubMed ID: 38497543
[TBL] [Abstract][Full Text] [Related]
2. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
Luo C; Yu T; Young KH; Yu L
J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
[TBL] [Abstract][Full Text] [Related]
4. Targeting HDACs for diffuse large B-cell lymphoma therapy.
Wu C; Song Q; Gao S; Wu S
Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
[TBL] [Abstract][Full Text] [Related]
5. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
[TBL] [Abstract][Full Text] [Related]
6. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
Wen T; Sun G; Jiang W; He X; Shi Y; Ma F; Liu P
EBioMedicine; 2023 Jan; 87():104420. PubMed ID: 36592514
[TBL] [Abstract][Full Text] [Related]
8. CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.
Sun Y; Gao Y; Chen J; Huang L; Deng P; Chen J; Chai KXY; Hong JH; Chan JY; He H; Wang Y; Cheah D; Lim JQ; Chia BKH; Huang D; Liu L; Liu S; Wang X; Teng Y; Pang D; Grigoropoulos NF; Teh BT; Yu Q; Lim ST; Li W; Ong CK; Huang H; Tan J
Cancer Lett; 2021 Sep; 521():268-280. PubMed ID: 34481935
[TBL] [Abstract][Full Text] [Related]
9. Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.
Xi M; Guo S; Bayin C; Peng L; Chuffart F; Bourova-Flin E; Rousseaux S; Khochbin S; Mi JQ; Wang J
Front Med; 2022 Jun; 16(3):442-458. PubMed ID: 34669156
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.
Roussel M; Le KS; Granier C; Llamas Gutierrez F; Foucher E; Le Gallou S; Pangault C; Xerri L; Launay V; Lamy T; Tartour E; Olive D; Fest T
Blood Adv; 2021 Apr; 5(7):1816-1829. PubMed ID: 33787861
[TBL] [Abstract][Full Text] [Related]
11. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
12. The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma.
Wang X; Wang D; Ding N; Mi L; Yu H; Wu M; Feng F; Hu L; Zhang Y; Zhong C; Ye Y; Li J; Fang W; Shi Y; Deng L; Ying Z; Song Y; Zhu J
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503063
[TBL] [Abstract][Full Text] [Related]
13. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
[TBL] [Abstract][Full Text] [Related]
14. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma.
Zhong M; Tan J; Pan G; Jiang Y; Zhou H; Lai Q; Chen Q; Fan L; Deng M; Xu B; Zha J
Front Oncol; 2021; 11():780118. PubMed ID: 34926293
[TBL] [Abstract][Full Text] [Related]
16. Lkb1 aggravates diffuse large B-cell lymphoma by promoting the function of Treg cells and immune escape.
Su X; Sun T; Li M; Xia Y; Li M; Wang D; Lu F; Ye J; Ji C
J Transl Med; 2022 Aug; 20(1):378. PubMed ID: 35986288
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B
Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068
[TBL] [Abstract][Full Text] [Related]
18. Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study.
Chen X; Wang H; Sun X; Su L; Liu F; Zhao K; Xu L; Wu S; Song T
Ann Transl Med; 2021 Dec; 9(24):1769. PubMed ID: 35071463
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
20. Human bone marrow-derived mesenchymal stem overexpressing microRNA-124-3p inhibit DLBCL progression by downregulating the NFATc1/cMYC pathway.
Zhao X; Xu M; Hu X; Ding X; Zhang X; Xu L; Li L; Sun X; Song J
Stem Cell Res Ther; 2023 May; 14(1):148. PubMed ID: 37248542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]